Vyndaqel Market Size Growth: From $2.22 Billion In 2026 To $4.19 Billion By 2030
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#Vyndaqel Market Set To Climb From $2.22 Billion In 2026 To $4.19 Billion By 2030#_x000D_
The vyndaqel market has experienced substantial expansion in recent years. It is projected to expand from $1.9 billion in 2025 to $2.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.4%. Historically, this growth can be ascribed to factors such as the approval of tafamidis, the scarcity of effective attr-cm treatments, advancements in cardiac imaging diagnostics, the expansion of rare disease programs, and a rise in cardiology referrals._x000D_
_x000D_
The vyndaqel market is anticipated to undergo significant expansion in the next few years. It is projected to achieve a market size of $4.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.1%. The primary drivers for this growth during the forecast period include an expanding aging population, heightened awareness regarding amyloid cardiomyopathy, the establishment of more specialty cardiology centers, greater acceptance of genetic testing, and increasing reimbursement support. Prominent trends expected in this period encompass the growing use of transthyretin stabilizers, an uptick in the diagnosis of ATTR cardiomyopathy, the availability of more oral therapies for rare cardiac conditions, a stronger emphasis on disease-modifying cardiac drugs, and the broader application of long-term amyloidosis treatments._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Vyndaqel Market Demand Drivers: What’s Powering Industry Growth?#_x000D_
The increasing adoption of precision medicine is projected to propel the growth of the Vyndaqel market moving forward. Precision medicine involves customizing medical treatment for individual patients based on their genetic, environmental, and lifestyle factors, leading to improved treatment effectiveness and better outcomes. The uptake of precision medicine is rising as both patients and healthcare providers increasingly prefer personalized therapies that ensure targeted treatment and more effective management of chronic diseases. Vyndaqel complements precision medicine by providing targeted therapy for transthyretin amyloidosis (ATTR), ensuring that patients most likely to benefit receive the treatment. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, a notable increase from six in 2022. Consequently, the growing adoption of precision medicine is driving the expansion of the Vyndaqel market. Rising healthcare expenditure is anticipated to fuel the expansion of the Vyndaqel market in the coming period. Healthcare expenditure refers to the total financial resources allocated to medical goods and services to maintain and enhance population health. Healthcare spending is increasing as an aging population requires more frequent medical care and long-term health services. Higher healthcare expenditure contributes to wider access to Vyndaqel by enabling greater funding for high-cost therapies and improving the diagnostic and care infrastructure necessary for managing transthyretin amyloid cardiomyopathy. For example, in April 2025, according to the Office for National Statistics, a UK-based government department, between 2023 and 2024, total healthcare spending increased by 6.5% in nominal terms, and by 2.4% in real terms after accounting for inflation. Therefore, the rising healthcare expenditure is driving the growth of the Vyndaqel market._x000D_
_x000D_
#Vyndaqel Market Segmentation And Category Overview#_x000D_
The vyndaqel market covered in this report is segmented – _x000D_
_x000D_
1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)_x000D_
2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)_x000D_
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies_x000D_
_x000D_
Subsegments:_x000D_
1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use _x000D_
2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use_x000D_
_x000D_
#Vyndaqel Market Innovation Trends: What Developments Are Reshaping The Industry?#_x000D_
Leading companies in the vyndaqel market are concentrating on expanding their facilities to produce active pharmaceutical ingredients, particularly transthyretin stabilizing therapeutics. These are designed to enhance cardiovascular outcomes and decrease hospital admissions for patients with ATTR-CM. A transthyretin stabilizing therapeutic refers to a pharmacological agent formulated to bind and stabilize transthyretin (TTR) tetramers, thereby preventing their breakdown into misfolded monomers which aggregate and form amyloid deposits. For example, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company specializing in genetic diseases, launched Attruby (acoramidis). This nearly complete (=90%) transthyretin (TTR) stabilizer was developed to address critical challenges in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) binds to and stabilizes TTR tetramers, preventing their dissociation into misfolded monomers that form amyloid deposits in cardiac tissue. The therapy delivers considerable cardiovascular benefits, including a reduction in cardiovascular death and cardiovascular-related hospitalizations, while preserving TTR’s native physiological functions, making it an effective treatment for improving patient outcomes and managing ATTR-CM._x000D_
_x000D_
#Vyndaqel Market Competitive Analysis Of Leading Industry Participants#_x000D_
Major companies operating in the vyndaqel market are Pfizer Inc. _x000D_
_x000D_
#View The Full Vyndaqel Market Report:#_x000D_
_x000D_
#Vyndaqel Market Regional Analysis: Which Region Leads By Revenue?#_x000D_
North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
